Sisram Medical Ltd. announced that the drug registration application of RT002 (DaxibotulinumtoxinA, the New Drug), a product sublicensed by Shanghai Fosun Pharmaceutical Industrial Development Company Limited (Shang Hai Fu Xing Yi Yao Chan Ye Fa Zhan You Xian Gong Si) which is indicated for the temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in adult patients, was accepted by the National Medical Products Administration. As at the date of this announcement, there was no Daxibotulinumtox A Botulinum Toxin product launched for sale in China. The Company was granted by Fosun Pharmaceutical Industrial in December 2022 the sublicense rights to use, import, sales and other commercial activities (excluding manufacturing) of the New Drug in the Region (i.e. Mainland China, Hong Kong and Macau Special Administrative Regions, hereinafter the same).

The head licensor, Revance Therapeutics Inc. which is based in the U.S., is still the owner of the New Drug in the region. The New Drug is a biological product which is intended for aesthetic indications. According to the sublicense agreement, the RT002 aesthetic indications apply to the treatment, minimization and/or eradication of, or the appearance of any lines and wrinkles on the body, including but not limited to facial glabellar lines and crow's feet.

Shareholders and investors are advised to exercise caution when dealing in the securities of the Company.